Related Experiment Video
Updated: Dec 29, 2025
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
Published on: January 14, 2020
[Organoids from pancreatic ductal adenocarcinoma]
Nelson Dusetti1, Juan Iovanna1
1Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a rapidly evolving and most frequently fatal disease. Despite the enormous progress in understanding the mechanisms related to PDAC pathogenesis, the impact on patient management has not yet been possible. Pancreatic organoids can be generated from small amounts of tissue. One of the most promising applications of organoids is that they can serve as a platform for selecting the right drugs for each patient. This approach has the potential to identify individual therapeutic vulnerabilities by allowing the personalization of treatments. However, these analyzes require several weeks before obtaining enough organoids from the same individual, to carry out the tests with several drugs, and to analyze the results, which limits its use in current clinical practice for the patients with a PDAC, whose it must be remembered that half die within 6 months of diagnosis. To overcome this obstacle, we assessed the ability of transcriptomic molecular signatures to identify patients with a particular sensitivity profile to a given treatment. The approaches based on transcriptomic profiling have the enormous advantage of using very little biological material and thus significantly reducing the time to arrive at the selection of more effective drugs to each patient.
Insights
Transcriptomic signatures can speed up personalized treatment selection for pancreatic cancer patients. This approach uses minimal tissue to identify effective drugs faster, overcoming organoid culture time limitations.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal cancer with limited treatment impact.
- Pancreatic organoids offer a platform for personalized drug screening but require extensive time.
- Current limitations hinder the clinical application of organoid-based drug selection for PDAC.
Purpose of the Study:
- To assess transcriptomic molecular signatures for predicting patient sensitivity to specific treatments.
- To overcome the time constraints associated with pancreatic organoid culture for drug screening.
- To enable faster selection of effective drugs for individual PDAC patients.
Main Methods:
- Utilized transcriptomic profiling to analyze molecular signatures in PDAC patients.
- Evaluated the ability of transcriptomic data to identify patient-specific drug sensitivity profiles.
- Compared transcriptomic approaches with traditional organoid culture methods.
Main Results:
- Transcriptomic profiling significantly reduces the time needed for drug sensitivity assessment.
- This method requires only a small amount of biological material.
- Identified potential for rapid identification of personalized therapeutic strategies.
Conclusions:
- Transcriptomic signatures offer a promising, time-efficient alternative for personalized drug selection in PDAC.
- This approach can accelerate the identification of effective treatments, improving patient management.
- Accelerated transcriptomic profiling holds potential to overcome critical clinical bottlenecks in PDAC therapy.
